Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Consolidated Net Income: 2019-2025

Historic Consolidated Net Income for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$112.7 million.

  • Beam Therapeutics' Consolidated Net Income fell 16.61% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$421.8 million, marking a year-over-year decrease of 191.13%. This contributed to the annual value of -$376.8 million for FY2024, which is 184.25% down from last year.
  • Beam Therapeutics' Consolidated Net Income amounted to -$112.7 million in Q3 2025, which was down 3.16% from -$109.3 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Consolidated Net Income registered a high of $142.8 million during Q4 2023, and its lowest value of -$200.4 million during Q1 2021.
  • Its 3-year average for Consolidated Net Income is -$77.1 million, with a median of -$96.5 million in 2023.
  • In the last 5 years, Beam Therapeutics' Consolidated Net Income slumped by 621.93% in 2021 and then soared by 472.27% in 2023.
  • Beam Therapeutics' Consolidated Net Income (Quarterly) stood at -$64.7 million in 2021, then skyrocketed by 40.73% to -$38.3 million in 2022, then skyrocketed by 472.27% to $142.8 million in 2023, then slumped by 163.33% to -$90.4 million in 2024, then fell by 16.61% to -$112.7 million in 2025.
  • Its Consolidated Net Income stands at -$112.7 million for Q3 2025, versus -$109.3 million for Q2 2025 and -$109.4 million for Q1 2025.